1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThe National Heart, Lung, and Blood Institute (NHLBI) Outstanding Investigator Award (OIA) provides experienced investigators with stable, long-term support to pursue innovative and ambitious research programs in heart, lung, blood, and sleep (HLBS) science.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Applicants must be current PDs/PIs on at least two NHLBI R01-equivalent awards or in the 6th/7th year of an NHLBI R35. Confirm the full requirements in the official notice before applying.
The current listing shows up to $700,000 direct costs/year for up to 7 years; total NHLBI commitment up to $20M/year. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional) are due April 28, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional) is funded by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health. This award promotes scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PDs/PIs) who are currently PDs/PIs on at least two NHLBI R01-equivalent awards and whose outstanding reco…
Research on Sickle Cell Disease and Sickle Cell Trait is sponsored by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health. R01 mechanism FOA encouraging research to understand pathophysiology, including inflammation and innate immune signaling in SCD and sickle cell trait, to improve prevention and treatment of complications.
Five NHLBI Catalyze Product Definition RFAs — HL-26-016 through HL-26-020 — carry an October 21, 2026 receipt date, budget caps of $300,000 to $400,000 per year, and roughly 8 new awards annually. The science is not the gate. An Accelerator Partner and a 0.25:1 non-federal cost match are, and both take longer to line up than the nine weeks you have left.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article